均相催化剂

Search documents
陕西瑞科:收到北交所上市申请审核问询函
Xin Jing Bao· 2025-07-31 13:49
Core Viewpoint - Shaanxi Ruike New Materials Co., Ltd. has received an inquiry letter from the Beijing Stock Exchange regarding its application for public stock issuance and listing, focusing on issues such as the clarity and stability of equity, product technological innovation, and compliance in production and operations [1] Company Overview - The company's main business includes the research, production, sales, processing, and recycling of deactivated precious metal catalysts [1] - Key products include heterogeneous catalysts, homogeneous catalysts, and ligands [1] Achievements and Recognition - The company has received multiple honors, including being recognized as a national intellectual property advantage enterprise, provincial industrial boutique, provincial enterprise technology center, provincial manufacturing single champion demonstration enterprise, provincial key construction project, and provincial small and medium-sized enterprise innovation research and development center [1]
凯立新材(688269):业绩符合预期,产销扩大盈利回暖,基础化工催化剂规模优势显现
Shenwan Hongyuan Securities· 2025-05-19 08:15
Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Insights - The company's performance met expectations, with sales expansion and profit recovery in the basic chemical catalyst sector, highlighting its scale advantages [1] - The company reported a total revenue of 1.687 billion yuan in 2024, a year-on-year decrease of 5.5%, and a net profit attributable to shareholders of 93 million yuan, down 18% year-on-year [6] - In Q1 2025, the company achieved a revenue of 626 million yuan, a year-on-year increase of 105.3%, and a net profit of 22 million yuan, up 90.5% year-on-year [6] Financial Data and Profit Forecast - The company forecasts total revenue of 1.971 billion yuan for 2025, with a year-on-year growth rate of 16.8% [5] - The projected net profit for 2025 is 150 million yuan, reflecting a year-on-year increase of 62.2% [5] - The earnings per share (EPS) is expected to be 1.15 yuan for 2025, with a projected price-to-earnings (PE) ratio of 28 [5] - The gross profit margin is anticipated to improve to 13.6% in 2025, up from 11.2% in 2024 [5] Company Performance and Market Dynamics - The company experienced a significant increase in catalyst sales volume in Q1 2025, with an overall sales increase of 188.87% year-on-year [6] - The pharmaceutical and basic chemical sectors saw sales growth of 174.88% and 285.60% respectively, indicating a strong recovery in demand [6] - The company is leveraging its R&D capabilities to enhance product offerings and expand into new markets, with a notable increase in revenue contribution from the basic chemical sector [6] Future Outlook - The company aims to maintain its profit forecasts for 2025-2026, with net profits projected at 150 million yuan and 215 million yuan respectively [6] - The introduction of new projects and products is expected to support future growth, with a focus on expanding its core competencies in various sectors [6]